Tyler Van Buren
Stock Analyst at TD Cowen
(1.62)
# 3,288
Out of 4,901 analysts
56
Total ratings
40%
Success rate
-4.86%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Initiates: Buy | n/a | $26.08 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $14.49 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $13.36 | +461.38% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $10.79 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $14.77 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $32.06 | +87.15% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $2.38 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $13.35 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $547.93 | +119.01% | 7 | Jul 23, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Buy | n/a | $22.57 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $20.92 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $85 | $109.85 | -22.62% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $55.14 | -45.59% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.61 | - | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $16.20 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $70.70 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $38.37 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $16.66 | +80.07% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $47.10 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.13 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $35.75 | +95.83% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.40 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.59 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.92 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.86 | +2,588.17% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $13.14 | +1,612.33% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $8.68 | +9,980.65% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $12.42 | +222.06% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $11.65 | +157.51% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.35 | +17,042.86% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.34 | +3,631.34% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.66 | +1,707.23% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $2.76 | +7,146.38% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.51 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.01 | - | 1 | Aug 4, 2017 |
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $26.08
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $14.49
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $13.36
Upside: +461.38%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $10.79
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $14.77
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $32.06
Upside: +87.15%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $2.38
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $13.35
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $547.93
Upside: +119.01%
Tectonic Therapeutic
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $22.57
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $20.92
Upside: -
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $109.85
Upside: -22.62%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $55.14
Upside: -45.59%
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.61
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $16.20
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $70.70
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $38.37
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $16.66
Upside: +80.07%
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $47.10
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.13
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $35.75
Upside: +95.83%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.40
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.59
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.92
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $1.86
Upside: +2,588.17%
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $13.14
Upside: +1,612.33%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $8.68
Upside: +9,980.65%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $12.42
Upside: +222.06%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $11.65
Upside: +157.51%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $0.35
Upside: +17,042.86%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.34
Upside: +3,631.34%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $1.66
Upside: +1,707.23%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $2.76
Upside: +7,146.38%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $3.51
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $16.01
Upside: -